Liver disease

Signs and symptoms

Some of the signs and symptoms of a liver disease are the following:

• Jaundice
• Confusion and altered consciousness caused by hepatic encephalopathy.{{cite web |url= https://www.lecturio.com/concepts/alcoholic-liver-disease/ | title= Alcoholic Liver Disease
• Thrombocytopenia and coagulopathy.
• Risk of bleeding symptoms, particularly taking place in the gastrointestinal tract

Types

There are more than a hundred different liver diseases. Some of the most common are:

• Fascioliasis, a parasitic infection of liver caused by a liver fluke of the genus FascioIa, mostly FascioIa hepatica.
• Hepatitis, inflammation of the liver, is caused by various viruses (viral hepatitis) also by some liver toxins (e.g. alcoholic hepatitis), autoimmunity (autoimmune hepatitis) or hereditary conditions.
• Alcoholic liver disease is a hepatic manifestation of alcohol overconsumption, including fatty liver disease, alcoholic hepatitis, and cirrhosis. Analogous terms such as "drug-induced" or "toxic" liver disease are also used to refer to disorders caused by various drugs.
• Fatty liver disease (hepatic steatosis) is a reversible condition where large vacuoles of triglyceride fat accumulate in liver cells. Non-alcoholic fatty liver disease is a spectrum of disease associated with obesity and metabolic syndrome.
• Hereditary diseases that cause damage to the liver include hemochromatosis, involving accumulation of iron in the body, and Wilson's disease. Liver damage is also a clinical feature of alpha 1-antitrypsin deficiency and glycogen storage disease type II.
• In transthyretin-related hereditary amyloidosis, the liver produces a mutated transthyretin protein which has severe neurodegenerative or cardiopathic effects. Liver transplantation can be curative.
• Gilbert's syndrome, a genetic disorder of bilirubin metabolism found in a small percent of the population, can cause mild jaundice.
• Cirrhosis is the formation of fibrous tissue (fibrosis) in the place of liver cells that have died due to a variety of causes, including viral hepatitis, alcohol overconsumption, and other forms of liver toxicity. Cirrhosis causes chronic liver failure.
• Primary liver cancer most commonly manifests as hepatocellular carcinoma or cholangiocarcinoma; rarer forms include angiosarcoma and hemangiosarcoma of the liver. (Many liver malignancies are secondary lesions that have metastasized from primary cancers in the gastrointestinal tract and other organs, such as the kidneys, lungs.)
• Primary biliary cirrhosis is a serious autoimmune disease of the bile capillaries.
• Primary sclerosing cholangitis is a serious chronic inflammatory disease of the bile duct, which is believed to be autoimmune in origin.
• Budd–Chiari syndrome is the clinical picture caused by occlusion of the hepatic vein.

File:Ground glass hepatocytes high mag cropped 2.jpg|Ground glass hepatocytes File:Primary biliary cirrhosis intermed mag much cropping.jpg|Primary biliary cirrhosis File:Buddchiari2.PNG|Budd–Chiari syndrome File:Non-alcoholic_fatty_liver_disease1.jpg| Micrograph of non-alcoholic fatty liver disease

Mechanisms

Liver diseases can develop through several mechanisms:

DNA damage

One general mechanism, increased DNA damage, is shared by some of the major liver diseases, including infection by hepatitis B virus or hepatitis C virus, heavy alcohol consumption, and obesity.

Viral infection by hepatitis B virus, or hepatitis C virus causes an increase of reactive oxygen species. The increase in intracellular reactive oxygen species is about 10,000-fold with chronic hepatitis B virus infection and 100,000-fold following hepatitis C virus infection.{{cite journal |last1= Iida-Ueno |first1= A |last2= Enomoto |first2= M |last3= Tamori |first3= A |last4= Kawada |first4= N |date= 21 April 2017 |title= Hepatitis B virus infection and alcohol consumption |journal= World Journal of Gastroenterology |volume= 23 |issue= 15 |pages= 2651–2659 |doi= 10.3748/wjg.v23.i15.2651 | pmid= 28487602

Alcohol consumption in excess causes a build-up of acetaldehyde. Acetaldehyde and free radicals generated by metabolizing alcohol induce DNA damage and oxidative stress. In addition, activation of neutrophils in alcoholic liver disease contributes to the pathogenesis of hepatocellular damage by releasing reactive oxygen species (which can damage DNA). The level of oxidative stress and acetaldehyde-induced DNA adducts due to alcohol consumption does not appear sufficient to cause increased mutagenesis. However, as reviewed by Nishida et al.,

Obesity is associated with a higher risk of primary liver cancer. As shown with mice, obese mice are prone to liver cancer, likely due to two factors. Obese mice have increased pro-inflammatory cytokines. Obese mice also have higher levels of deoxycholic acid, a product of bile acid alteration by certain gut microbes, and these microbes are increased with obesity. The excess deoxycholic acid causes DNA damage and inflammation in the liver, which, in turn, can lead to liver cancer.

Other relevant aspects

Several liver diseases are due to viral infection. Viral hepatitides such as Hepatitis B virus and Hepatitis C virus can be vertically transmitted during birth via contact with infected blood. According to a 2012 NICE publication, "about 85% of hepatitis B infections in newborns become chronic". In occult cases, Hepatitis B virus is present by hepatitis B virus DNA, but testing for HBsAg is negative. High consumption of alcohol can lead to several forms of liver disease including alcoholic hepatitis, alcoholic fatty liver disease, cirrhosis, and liver cancer. In the earlier stages of alcoholic liver disease, fat builds up in the liver's cells due to increased creation of triglycerides and fatty acids and a decreased ability to break down fatty acids. Progression of the disease can lead to liver inflammation from the excess fat in the liver. Scarring in the liver often occurs as the body attempts to heal and extensive scarring can lead to the development of cirrhosis in more advanced stages of the disease. Insight into the exact causes and mechanisms mediating pathophysiology of the liver is quickly progressing due to the introduction new technological approaches like Single cell sequencing and kinome profiling

Air pollutants

Particulate matter or carbon black are common pollutants. They have a direct toxic effect on the liver; cause inflammation of liver caused by and thereby impact lipid metabolism and fatty liver disease; and can translocate from the lungs to the liver.

Because particulate matter and carbon black are very diverse and each has different toxicodynamics, detailed mechanisms of translocation are not clear. Water-soluble fractions of particulate matter are the most important part of translocation to the liver, through extrapulmonary circulation. When particulate matter gets into the bloodstream, it combines with immune cells and stimulates innate immune responses. Pro-inflammatory cytokines are released and cause disease progression.

Diagnosis

A number of liver function tests are available to test the proper function of the liver. These test for the presence of enzymes in blood that are normally most abundant in liver tissue, metabolites or products. serum proteins, serum albumin, serum globulin, alanine transaminase, aspartate transaminase, prothrombin time, partial thromboplastin time.

Imaging tests such as transient elastography, ultrasound and magnetic resonance imaging can be used to show the liver tissue and the bile ducts. Liver biopsy can be performed to examine liver tissue to distinguish between various conditions; tests such as elastography may reduce the need for biopsy in some situations.

In liver disease, prothrombin time is longer than usual. In addition, the amounts of both coagulation factors and anticoagulation factors are reduced as a diseased liver cannot productively synthesize them as it did when healthy. Nonetheless, there are two exceptions in this falling tendency: coagulation factor VIII and von Willebrand factor, a platelet adhesive protein. Both inversely rise in the setting of hepatic insufficiency, thanks to the drop of hepatic clearance and compensatory productions from other sites of the body. Fibrinolysis generally proceeds faster with acute liver failure and advanced stage liver disease, unlike chronic liver disease in which concentration of fibrinogen remains unchanged.

A previously undiagnosed liver disease may become evident first after autopsy. Following are gross pathology images: File:Gross pathology of alcoholic liver cirrhosis.jpg|Diffuse cirrhosis File:Wątroba marska (Ultima Thule).jpg|Macronodular cirrhosis File:Nutmeg liver (crop).jpg|Nutmeg texture of congestive hepatopathy

Treatment

Anti-viral medications are available to treat infections such as hepatitis B. Other conditions may be managed by slowing down disease progression, for example:

• By using steroid-based drugs in autoimmune hepatitis.
• Regularly removing a quantity of blood from a vein (venesection) in the iron overload condition, hemochromatosis.
• Wilson's disease, a condition where copper builds up in the body, can be managed with drugs that bind copper, allowing it to be passed from the body in urine.
• In cholestatic liver disease, (where the flow of bile is affected due to cystic fibrosis) a medication called ursodeoxycholic acid may be given.

Epidemiology

Liver diseases, including conditions such as non-alcoholic fatty liver disease (NAFLD), alcohol-related liver disease (ALD), and viral hepatitis, are significant public health concerns worldwide. In the United States, NAFLD is the most common chronic liver condition, affecting approximately 24% of the population, with the prevalence rising due to increasing rates of obesity and metabolic syndrome. Alcohol-related liver disease accounts for about 4.5% of liver-related deaths globally, underscoring the substantial burden of alcohol misuse. Viral hepatitis, primarily hepatitis B and hepatitis C, remains a leading cause of liver cirrhosis and liver cancer worldwide, despite advances in antiviral therapies and vaccination efforts. Additionally, recent studies have highlighted lean steatotic liver disease (SLD), a subset of NAFLD, affecting over 12% of U.S. adults even in the absence of obesity. These data emphasize the importance of early detection and targeted interventions to manage liver disease and its associated complications effectively. Under the new definition of MAFLD, counts of global prevalence jumped to over 50%.

New research reports the prevalence of lean steatotic liver disease (SLD) in the United States using data from the National Health and Nutrition Examination Survey (2017-2023), researchers estimated the age-adjusted prevalence of lean SLD at 12.8%. This includes 9.3% for lean metabolic dysfunction-associated steatotic liver disease, 1.3% for metabolic dysfunction and alcohol-related steatotic liver disease, and 1.0% for alcohol-related liver disease.

References

References

1. "Liver Diseases".
2. "NHS Choices".
3. "Liver Disease {{!}} NIDDK".
4. (2007). "Coagulopathy in liver disease.". Current Treatment Options in Gastroenterology.
5. (2011-07-14). "The Coagulopathy of Chronic Liver Disease". Massachusetts Medical Society.
6. "Liver disease – NHS Choices".
7. "CDC – Fasciola".
8. "Hepatitis".
9. {{MedlinePlusEncyclopedia. 000281. Alcoholic liver disease
10. "Hepatic steatosis".
11. "Non-alcoholic fatty liver disease – NHS Choices".
12. "Hemochromatosis".
13. "Alpha-1 Antitrypsin Deficiency".
14. (1993). "Glycogen Storage Disease Type II (Pompe Disease)". University of Washington, Seattle.
15. "Transthyretin amyloidosis".
16. "Gilbert syndrome".
17. "Cirrhosis: MedlinePlus Medical Encyclopedia".
18. "Liver cancer – Hepatocellular carcinoma: MedlinePlus Medical Encyclopedia".
19. "Primary biliary cirrhosis: MedlinePlus Medical Encyclopedia".
20. "Sclerosing cholangitis: MedlinePlus Medical Encyclopedia".
21. "Hepatic vein obstruction (Budd-Chiari): MedlinePlus Medical Encyclopedia".
22. (12 April 2022). "Chronic Liver Disease/Cirrhosis | Johns Hopkins Medicine Health Library".
23. (December 2016). "Occurrence, Biological Consequences, and Human Health Relevance of Oxidative Stress-Induced DNA Damage". Chemical Research in Toxicology.
24. (December 2012). "Oxidatively induced DNA damage: mechanisms, repair and disease". Cancer Letters.
25. (2013). "Oxidative stress and epigenetic instability in human hepatocarcinogenesis". Digestive Diseases.
26. (June 2014). "Exploration of liver cancer genomes". Nature Reviews. Gastroenterology & Hepatology.
27. (May 2013). "Genetics and epigenetics of liver cancer". New Biotechnology.
28. (December 2010). "Formation of acetaldehyde-derived DNA adducts due to alcohol exposure". Chemico-Biological Interactions.
29. (July 2016). "Interplay of genetic and epigenetic alterations in hepatocellular carcinoma". Epigenomics.
30. (5 January 2018). "Drinking alcohol causes cancer by 'damaging DNA' - Independent.ie".
31. (August 2012). "Inflammation in alcoholic liver disease". Annual Review of Nutrition.
32. (2013). "Epigenetic effects of ethanol on the liver and gastrointestinal system". Alcohol Research.
33. (2016). "Obesity and Cancer". Recent Results in Cancer Research. Fortschritte der Krebsforschung. Progres dans les Recherches Sur le Cancer.
34. (2013-06-26). "Gut Bugs Could Explain Obesity-Cancer Link | Science | AAAS".
35. (September 2014). "Vertical transmission of hepatitis C virus: systematic review and meta-analysis". Clinical Infectious Diseases.
36. (July 2014). "Hepatitis B virus: where do we stand and what is the next step for eradication?". World Journal of Gastroenterology.
37. (12 December 2012). "Hepatitis B and C: ways to promote and offer testing to people at increased risk of infection {{!}} Guidance and guidelines {{!}} NICE".
38. (January 2012). "Molecular mechanisms underlying occult hepatitis B virus infection". Clinical Microbiology Reviews.
39. (September 2014). "Alcoholic liver disease: treatment". World Journal of Gastroenterology.
40. (September 2014). "New advances in molecular mechanisms and emerging therapeutic targets in alcoholic liver diseases". World Journal of Gastroenterology.
41. (December 2016). "Gut microbiome and liver diseases". Gut.
42. (March 2021). "Drug Discovery in Liver Disease Using Kinome Profiling". International Journal of Molecular Sciences.
43. (June 2014). "The role of air pollutants in initiating liver disease". Toxicological Research.
44. {{MedlinePlusEncyclopedia. 003436. Liver function tests
45. (August 2017). "Use of Liver Imaging and Biopsy in Clinical Practice". The New England Journal of Medicine.
46. Barton, Cassie A.. (2016). "Treatment of Coagulopathy Related to Hepatic Insufficiency". Ovid Technologies (Wolters Kluwer Health).
47. (June 2010). "Antiviral treatment of chronic hepatitis B virus infections". Viruses.
48. (2011-12-02). "Autoimmune Hepatitis: A Guide for Practicing Clinicians". Springer Science & Business Media.
49. "Phlebotomy Treatment {{!}} Treatment and Management {{!}} Training & Education {{!}} Hemochromatosis (Iron Storage Disease) {{!}} NCBDDD {{!}} CDC".
50. "Wilson Disease".
51. (2014-02-20). "Liver Disease in Children". Cambridge University Press.
52. (2017). "Ursodeoxycholic acid for liver disease related to cystic fibrosis". Cochrane Database of Systematic Reviews.
53. (2016). "Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes". Hepatology.
54. (2023). "The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review". Hepatology.
55. (2019-12-13). "Global Burden of Alcohol Use Disorders and Alcohol Liver Disease". Biomedicines.
56. (2023). "Global prevalence of hepatitis B or hepatitis C infection among patients with tuberculosis disease: systematic review and meta-analysis". eClinicalMedicine.
57. (2025-01-11). "Current Burden of Lean Metabolic Dysfunction-Associated Steatotic Liver Disease Among US Adults, 2017–2023". Alimentary Pharmacology & Therapeutics.
58. (February 2021). "Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Adults". Clinical Gastroenterology and Hepatology.
59. (2025). "Current Burden of Lean Metabolic Dysfunction-Associated Steatotic Liver Disease Among US Adults, 2017–2023". Alimentary Pharmacology & Therapeutics.
60. (2025-01-16). "Lean Steatotic Liver Disease Affects 12% of US Adults, Study Finds".